What the Current Clinical Evidence Shows Phase 2 trial data published in the NEJM in 2023 show gastrointestinal events including nausea were the most common side effects, were transient and self-limiting in most participants, and were more frequent at higher doses
Available drugs produced, on average, about 5% body weight reduction meaningful for metabolic health, but nowhere near what patients hoped for
Our team of experts is dedicated to providing personalized, safe, and effective programs that incorporate GLP-1 in a way that suits your individual needs
A cultural shift to more tailored wellbeing strategies can improve health outcomes and boost company performance
symptoms may continue for several days as drug levels decline
New to handling these compounds